Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + R-Chemo in Aggressive B-cell Lymphoma
NCT04152577Phase 4Unknown
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jun 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lenalidomide in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Overall Response Rate. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04152577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152577.